Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Infra-Red Technology Based Test Can Rapidly Predict Severe COVID-19

By LabMedica International staff writers
Posted on 18 Aug 2021
Scientists have developed a way of using infra-red technology to rapidly test which patients are most at risk of becoming severely unwell from COVID-19.

In a small pilot study of COVID-19 patients in India that led by QIMR Berghofer Medical Research Institute (Brisbane, Australia) and the Indian Institute of Technology (Maharashtra, India), the test performed with 85% accuracy. More...
The researchers hope that the test could in future be used to triage patients in areas with large outbreaks of the disease.

The test was developed through an international collaboration between academia and industry using blood samples from 128 COVID-19 patients in Mumbai, India. Infra-red spectra measure the levels of different chemical groups in a sample. The team then used artificial intelligence to develop an algorithm to work out which chemical groups, or ‘signatures’, were correlated with patients who became severely unwell.

“We found there were measurable differences in the infra-red spectra in the patients who became severely unwell. In particular, there were differences in two infra-red regions that correspond to sugar and phosphate chemical groups, as well as primary amines, which occur in specific types of proteins,” said Associate Professor Michelle Hill, head of QIMR Berghofer’s Precision and Systems Biomedicine Research Group.

“We also found that having diabetes was a predictor of becoming severely unwell in this group of patients, so we fed this information into the algorithm. We then tested the algorithm on blood samples from a separate group of 30 patients from Mumbai and found it was 85 per cent accurate in predicting which patients would become severely ill,” Associate Professor Hill said. “However, it did result in more ‘false positives’ than predictions that were based solely on the clinical risk factors of age, sex, hypertension and diabetes. We hope that with more testing we can reduce these false positives.”

“From our study, we can say that there is a correlation between blood chemical signature and becoming severely unwell with COVID-19,” said Professor Sanjeeva Srivastava, head of the Proteomics Facility at the Indian Institute of Technology. She added that the finding that there were chemical differences in more severe COVID-19 cases was consistent with published studies conducted in other countries.

Related Links:
QIMR Berghofer Medical Research Institute
Indian Institute of Technology



Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.